These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17934830)

  • 21. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
    Wada F; Murase K; Isomoto H; Soda H; Takeshima F; Omagari K; Mizuta Y; Tsukamoto K; Murata I; Kohno S
    J Int Med Res; 2002; 30(4):413-21. PubMed ID: 12235924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
    Ariizumi K; Ohara S; Koike T; Inomata Y; Iijima K; Sekine H; Noguchi M; Sugiyama K; Eda Y; Kayaba S; Kawamura M; Shimosegawa T
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1428-34. PubMed ID: 16911688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
    Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
    Okamura Y; Takeno S; Takahashi Y; Moroga T; Yamashita S; Kawahara K
    Ann Thorac Cardiovasc Surg; 2013; 19(2):136-9. PubMed ID: 22971805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
    Shimatani T; Inoue M; Kuroiwa T; Horikawa Y
    Aliment Pharmacol Ther; 2004 Jan; 19(1):113-22. PubMed ID: 14687173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
    Lin CJ; Yang JC; Uang YS; Chern HD; Wang TH
    Pharmacotherapy; 2003 Jun; 23(6):711-9. PubMed ID: 12820812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
    Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
    J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract]   [Full Text] [Related]  

  • 37. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
    Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
    Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
    Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.